GlassScriptPhysician profile
Erwin V Torralba
NPI 1245802545
$414.71
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $186.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $107.16 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $71.31 | 2021-2022 | |
| Cvrx, INC. | $57.53 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.56 | 2022 | |
| Novartis Pharmaceuticals Corporation | $37.41 | 2021-2022 | |
| Esperion Therapeutics, INC. | $23.89 | 2021 | |
| Amgen INC. | $20.54 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.97 | 2021 | |
| Pfizer INC. | $14.76 | 2022 | |
| Medtronic, INC. | $14.58 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erwin Torralba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.